Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25763 | 1.00 | LMNA (0.43) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL26110 | 0.89 | LMNA (0.44) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL24651 | 0.86 | LMNA (0.43) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL24652 | 0.86 | LMNA (0.43) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL7200664 | 0.83 | CYP1A2 (0.41) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL9457632 | 0.83 | ALDH1A1 (0.44) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL25502 | 0.82 | RECQL (0.44) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL25503 | 0.82 | RECQL (0.44) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL636942 | 0.81 | MEN1 (0.40) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL24993 | 0.81 | MEN1 (0.40) | LMNASMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3722285-B1 | PROCESS FOR PREPARING MIRABEGRON ENACARBIL | TIEFENBACHER ALFRED E GMBH & CO KG (DE) | 2022-03-30 | — | — | EP | claimed |
| EP-3722285-A1 | PROCESS FOR PREPARING MIRABEGRON ENACARBIL | Alfred E. Tiefenbacher (GmbH & Co. KG) (DE) | 2020-10-14 | — | — | EP | claimed |
| EP-3722285-B1 | PROCESS FOR PREPARING MIRABEGRON ENACARBIL | TIEFENBACHER ALFRED E GMBH & CO KG (DE) | 2022-03-30 | — | — | EP | disclosed |
| EP-3722285-A1 | PROCESS FOR PREPARING MIRABEGRON ENACARBIL | Alfred E. Tiefenbacher (GmbH & Co. KG) (DE) | 2020-10-14 | — | — | EP | disclosed |
| EP-3489224-A1 | MIRABEGRON PRODRUGS | Alfred E. Tiefenbacher (GmbH & Co. KG) (DE) | 2019-05-29 | — | — | EP | disclosed |
| EP-3360866-B1 | MIRABEGRON PRODRUGS | TIEFENBACHER ALFRED E GMBH & CO KG (DE) | 2019-01-02 | — | — | EP | disclosed |
| US-20160090353-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2016-03-31 | — | — | US | disclosed |
| US-9238616-B2 | Prodrugs of gaba analogs, compositions and uses thereof | XENOPORT, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20150307442-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | ARBOR PHARMACEUTICALS, LLC | 2015-10-29 | — | — | US | disclosed |
| US-20130102641-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-8367722-B2 | Methods of using prodrugs of pregabalin | XENOPORT, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20030092755-A1 | Novel prodrugs for antimicrobial amidines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-15 | — | — | US | disclosed |
| US-6503940-B2 | Aids therapy | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2003-01-07 | — | — | US | disclosed |
| WO-2002100347-A2 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-6486200-B1 | Prodrugs for antimicrobial amidines | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2002-11-26 | — | — | US | disclosed |
| EP-1242059-A2 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020019437-A1 | Novel prodrugs for antimicrobial amidines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-02-14 | — | — | US | disclosed |
| US-6200976-B1 | FOR TREATING THROMBOSIS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-03-13 | — | — | US | disclosed |
| WO-2001003685-A2 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2001-01-18 | — | — | WO | disclosed |
| US-6114532-A | ANTICOAGULANT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160090353-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB2, GABRB3 | LMNA 3012/4885SMN1; SMN2 1234/4885ALDH1A1 298/4885 |
| US-20150307442-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB2, GABRB3 | LMNA 3012/4885SMN1; SMN2 1234/4885ALDH1A1 298/4885 |
| US-20130102641-A1 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF | GABRB1, GABRB2, GABRB3 | LMNA 3012/4885SMN1; SMN2 1234/4885ALDH1A1 298/4885 |
| US-20030092755-A1 | Novel prodrugs for antimicrobial amidines | NR1H3, APEH, NR1H2 | LMNA 4029/4885SMN1; SMN2 3797/4885ALDH1A1 976/4885 |
| US-20020019437-A1 | Novel prodrugs for antimicrobial amidines | NR1H3, APEH, NR1H2 | LMNA 4029/4885SMN1; SMN2 3797/4885ALDH1A1 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.